Navigation Links
Strativa Pharmaceuticals Announces Preliminary Results from ONCONASE(R) Phase IIIb Clinical Trial
Date:5/29/2008

regimen before entering this clinical trial. Patients who received ONCONASE plus doxorubicin experienced a MST of 10.5 months compared with 8.7 months for those patients who received doxorubicin (unadjusted log rank p=0.016).

Based on the preliminary statistical analysis of the data, Alfacell will continue with the planned submission of the remaining components of the ONCONASE rolling NDA. Pending completion of the analysis of the data and further discussions with the FDA, the company currently estimates that the NDA submission will be completed by the end of calendar year 2008.

John MacPhee, president of Strativa Pharmaceuticals, said, "We remain optimistic about the potential of ONCONASE for patients living with unresectable malignant mesothelioma. We are committed to collaborating with Alfacell as they continue with the planned submission of the NDA."

In January 2008, Strativa entered into an exclusive licensing agreement under which Strativa received commercialization rights in the U.S. to Alfacell's ONCONASE (ranspirnase). In return for the commercialization rights to ONCONASE, Strativa paid Alfacell an initial payment of $5 million, which was incurred as a research and development (R&D) expense in the first quarter 2008. Strativa will also pay Alfacell a development milestone upon FDA approval. In addition to royalties on sales, Alfacell may receive milestone payments on future sales. Alfacell will also retain the right to co-promote ONCONASE in the future.

ONCONASE has been granted fast track status and orphan-drug designation for the treatment of malignant mesothelioma by the FDA. Additionally, ONCONASE has been granted orphan-drug designation in the European Union and Australia.

About Strativa

Strativa Pharmaceuticals is the proprietary products division of Par Pharmaceutical, Inc. Strativa is committed to developing and marketing novel prescription drugs. Its initial focus is on supportive care therapeutics in HIV
'/>"/>

SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Strativa Pharmaceuticals Announces Phase III Results for Loramyc(R) to Treat Oropharyngeal Candidiasis
2. Access Pharmaceuticals Presents Favorable Ovarian Cancer Data and Clinical Update on ProLindac(TM) Development at Prestigious International Symposium
3. Access Pharmaceuticals Presents New Data on the Companys Cobalamin(TM) Technology at an International Polymer Therapeutics Symposium
4. Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
5. QuatRx Pharmaceuticals Announces Presentation of Further Data from Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy
6. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
7. Tioga Pharmaceuticals Asimadoline Demonstrates Positive Results in a Phase 2b Clinical Trial for the Treatment of Irritable Bowel Syndrome
8. Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results
9. Memory Pharmaceuticals Highlights Progress with Key Programs at its R&D Day
10. Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute
11. VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 /PRNewswire-iReach/ -- ChinaMarketResearchReports.com adds ... to its store . (Photo: ... of population, consumption upgrade and policy support, ... seen rapid development over the years, with total ... 2006 to 9.85 billion yuan in 2012. ...
(Date:1/15/2014)... Jan. 15, 2014 As health officials across ... flu virus, select Meijer pharmacies in Michigan ... and strep throat to eligible patients, enabling Meijer pharmacists ... matching prescriptions, under strict protocol set by a physician ... Grand Rapids, Mich. -based retailer is collaborating with ...
(Date:1/15/2014)... Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... has received commitments from institutional investors to purchase ... Company,s common stock in an at-the-market registered direct ... The Company entered into definitive purchase ... Company agreed to sell an aggregate of 3,603,603 ...
Breaking Medicine Technology:Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3
... GP Strategies Corporation (NYSE: GPX ... provider General Physics Corporation (GP), announced today that its ... repurchase program, replacing the existing authorization which has approximately ... management, at its discretion, to repurchase shares from time ...
... 27, 2011 Hologic, Inc. (Hologic or the Company) ... and supplier of premium diagnostics, medical imaging systems and ... women, today announced plans to release its fourth quarter ... close. In conjunction with the release, management will host ...
Cached Medicine Technology:GP Strategies Announces $5 Million Share Repurchase Program 2Hologic to Release Fourth Quarter Fiscal 2011 Operating Results on Monday, November 7, 2011 2
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
(Date:4/14/2014)... A new study shows that moderate to severe ... risk of stroke, cancer and death. , Results of ... to severe obstructive sleep apnea were four times more ... times more likely to have a stroke (HR = ... (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... Dallas study involving serious youth offenders, the answer to one ... seven years: "How long do you think you,ll live?", According ... offending over time., Author Dr. Alex Piquero said the study ... of them offend at very high rates and commit more ... much later in life offend much less., "In a lot ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... Lower weight babies and babies who aren,t breastfed ... risk of developing chronic inflammation and related health ... study. , "There were good reasons to hypothesize ... inflammation in adulthood," says Thomas McDade (Northwestern University), ... in the Child & Brain Development program. "It ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2Health News:Low birth weight, less breastfeeding create later health risks 2
... induce a rapid weight decline, mainly in the first ... regain, despite continued dieting. The partial regain may ... now shows that improvements to health remain even if ... online in Diabetes Care (Print: February 2012) ...
... director of fellowship training in female pelvic medicine and ... Temple, Texas, has received an Honorary Fellowship from the ... Gynaecologists (RANZCOG). He has served as a mentor to ... Australia on a number of occasions for lectures and ...
... Reinberg HealthDay Reporter , TUESDAY, Dec. 20 (HealthDay ... who keep their blood pressure levels under control may add ... fact, those in the study who took medicine to lower ... risk of dying from cardiovascular disease over a 20-year period, ...
... New research from the University of Michigan suggests obesity can ... free market policies. A study of 26 wealthy nations ... restaurants per capita had much higher obesity rates compared to ... capita. "It,s not by chance that countries with ...
... GABLES, FL Approximately 80,000 industrial chemicals are in ... commerce each year in the United States, according to ... risks from exposure to harmful substances, James Englehardt, professor ... Miami, is proposing a new technique that is more ...
... of patients who see an internal medicine specialist before major ... patients to 90 per cent, new research has found. ... commonly agreed upon standards for which patients should have such ... Ka Shing Knowledge Institute of St. Michael,s Hospital and the ...
Cached Medicine News:Health News:More reasons to keep this New Year's weight loss resolution uncovered by Ben-Gurion U researchers 2Health News:More reasons to keep this New Year's weight loss resolution uncovered by Ben-Gurion U researchers 3Health News:Scott & White physician recognized by Royal Australian and New Zealand College 2Health News:Treating High Blood Pressure May Add Years to Life 2Health News:Treating High Blood Pressure May Add Years to Life 3Health News:Supersized market economy, supersized belly: Wealthier nations have more fast food and more obesity 2Health News:UM researcher develops new way to assess risk for chemicals 2Health News:Pre-surgery exam rates vary widely among hospitals 2
The Surgifresh mini has the same rugged construction as the Plume-inator. It is the ideal size for operating room, clinic and office settings. This unit includes a filter test button, hospital grade ...
... for the phakic eye, clinically validated ... of vision and visual acuity comparable ... is compatible with current cataract surgical ... the correction of myopia in whole ...
... VitalVac's advanced technology makes ... to evacuate surgical plume. ... O.R. environment is "smoke-free", ... staff safe from potentially ...
Stryker Instruments, the leader in surgical helmets, offers its 4th generation of personal protection systems for todays surgical environment the Sterishield T4 System....
Medicine Products: